BR0315569A - Apresentação farmacêutica de liberação prolongada contendo alfuzosina - Google Patents

Apresentação farmacêutica de liberação prolongada contendo alfuzosina

Info

Publication number
BR0315569A
BR0315569A BR0315569-2A BR0315569A BR0315569A BR 0315569 A BR0315569 A BR 0315569A BR 0315569 A BR0315569 A BR 0315569A BR 0315569 A BR0315569 A BR 0315569A
Authority
BR
Brazil
Prior art keywords
alfuzosine
release
functional layer
prolonged release
single functional
Prior art date
Application number
BR0315569-2A
Other languages
English (en)
Inventor
Narayanan Badri Viswanathan
Sankar Ramakrishnan
Rajeev Singh Raghuvanshi
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0315569A publication Critical patent/BR0315569A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"APRESENTAçãO FARMACêUTICA DE LIBERAçãO PROLONGADA CONTENDO ALFUZOSINA". A presente invenção refere-se a composições farmacêuticas de alfuzosina ou sal farmaceuticamente aceitável, solvato, enantiómeros ou misturas desses, que liberam o ingrediente ativo durante um período de tempo prolongado. A composição farmacêutica pode ser uma apresentação farmacêutica oral de liberação prolongada que inclui uma camada funcional única e, opcionalmente, uma ou mais camadas não funcionais adjacentes à camada única funcional. A camada única funcional inclui alfuzosina ou seus sais farmaceuticamente aceitáveis, solvatos, enantiómeros ou misturas desses e um ou mais ingredientes retardadores de liberação.
BR0315569-2A 2002-10-22 2003-10-22 Apresentação farmacêutica de liberação prolongada contendo alfuzosina BR0315569A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1056DE2002 2002-10-22
PCT/IB2003/004677 WO2004037228A1 (en) 2002-10-22 2003-10-22 Sustained release compositions containing alfuzosin

Publications (1)

Publication Number Publication Date
BR0315569A true BR0315569A (pt) 2005-08-30

Family

ID=34631110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315569-2A BR0315569A (pt) 2002-10-22 2003-10-22 Apresentação farmacêutica de liberação prolongada contendo alfuzosina

Country Status (8)

Country Link
US (1) US20060147530A1 (pt)
EP (1) EP1556014A1 (pt)
CN (1) CN1720026A (pt)
AU (1) AU2003278407A1 (pt)
BR (1) BR0315569A (pt)
EA (1) EA200500672A1 (pt)
MX (1) MXPA05004338A (pt)
WO (1) WO2004037228A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
US8206742B2 (en) * 2006-01-12 2012-06-26 Wockhardt Ltd. Sustained release compositions of alfuzosin
US20070292505A1 (en) * 2006-06-15 2007-12-20 Abrika Pharmaceuticals, Inc. Controlled release alfuzosin hydrochloride formulation
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
RU2442570C1 (ru) * 2010-11-18 2012-02-20 Ангук Фармасьютикал Ко., Лтд. Таблетка с замедленным высвобождением, содержащая гидрохлорид альфузозина
CN105287422A (zh) * 2015-12-07 2016-02-03 黑龙江省智诚医药科技有限公司 一种盐酸阿夫唑嗪缓释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
KR100364328B1 (ko) * 1996-08-29 2002-12-26 사노피-신델라보 알푸조신 염산염의 제어방출 정제
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu

Also Published As

Publication number Publication date
EP1556014A1 (en) 2005-07-27
WO2004037228A8 (en) 2004-08-26
AU2003278407A1 (en) 2004-05-13
MXPA05004338A (es) 2005-06-22
US20060147530A1 (en) 2006-07-06
EA200500672A1 (ru) 2005-12-29
CN1720026A (zh) 2006-01-11
WO2004037228A1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
NO20070578L (no) Oral doseringsform sikret mot misbruk inneholdende (1,2R)-3-(3-dimetylammino-l-etyl-2-metyl-propyl)-fenol
BR0001515A (pt) Composições de espuma estáveis
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
IS7142A (is) Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
EA200400471A1 (ru) Оральная дозированная форма пропиверина
CY1107966T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν μετφορμινη και γλιβενκλαμιδη για τη θεραπεια του σακχαρωδους διαβητη τυπου ii
EE05400B1 (et) Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
HUP0300684A2 (hu) Szomatosztatin analógok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20003196D0 (no) Umiddelbart smeltende doseringsformulering
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
EP1041987A4 (en) COMBINATION OF OPIOID AGONISTS AND ANTAGONISTS
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
ATE538797T1 (de) Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
BR0114100A (pt) Formulações de liberação controlada para administração oral
UY27979A1 (es) Indoles sustituidos en posición 2,4
BRPI0414558A (pt) composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide
BR112022002436A2 (pt) Composição farmacêutica oral contendo composto heterocíclico
BRPI0507735A (pt) composição para administração oral de cloridrato de tamsulosin e formulação de gránulo de liberação controlada compreendendo a mesma
ATE324112T1 (de) Topische behandlung bei der mastalgie
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A , 6A , E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.